Lantern Pharma (LTRN) Cash from Investing Activities (2020 - 2026)

Lantern Pharma (LTRN) has 7 years of Cash from Investing Activities data on file, last reported at $4.2 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 31.2% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.1 million (up 68.43% YoY) and the FY2025 annual result came in at $11.1 million, up 228.16% from the prior year.
• Cash from Investing Activities climbed to $4.2 million in Q1 2026, from -$1.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $5.9 million in Q3 2025 to a low of -$1.7 million in Q4 2025.
• A 5-year average of $1.1 million and a median of $231729.0 in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 644.35% — and 2025, when it jumped 1878.24%.
• Tracing LTRN's Cash from Investing Activities over 5 years: stood at $602861.0 in 2022, then slumped by 57.51% to $256181.0 in 2023, then jumped by 1245.63% to $3.4 million in 2024, then slumped by 149.43% to -$1.7 million in 2025, then soared by 349.42% to $4.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $4.2 million (Q1 2026), -$1.7 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.